Full Breakdown
Wegovy Oral Semaglutide Pill Begins Private Sale in the UK
7/7/2026, 5:21:44 AM
Private Launch of Wegovy Oral Semaglutide
The Wegovy tablet, containing semaglutide, was approved by the MHRA in June 2026 and entered pharmacies on 6 July 2026. It requires a private prescription after a clinical assessment and is not yet on the NHS; NICE’s cost-effectiveness review is pending.
Background & Context
Wegovy has been used as a weekly injection; the oral form offers a needle-free alternative. Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1 to suppress appetite. Novo Nordisk estimates obesity affects about 16 million UK adults.
Key Figures & Groups
Novo Nordisk manufactures the pill; the MHRA granted authorisation; NICE will assess cost-effectiveness; the NPA represents pharmacy interests; Boots, Superdrug and Simple Online Pharmacy are dispensing it.
Data & Statistics
OASIS 4 showed a mean 16.6 % weight loss with the 25 mg tablet versus 2.7 % with placebo. Private prices range from £69 for the 1.5 mg starter dose to £229 for 25 mg. A survey of 310 pharmacies found 76 % expect a surge in patients, 49 % report more enquiries, and 97 % fear counterfeit tablets.
Why It Matters
The oral pill widens access for patients reluctant to inject, potentially boosting uptake of proven obesity therapy. Private cost and lack of NHS coverage raise equity concerns, while counterfeit risk threatens safety.
Official Statements & Responses
Adam Burt (Novo Nordisk) said the pill adds a long-term weight-management option for a disease affecting 16 million people, but stressed NHS cost-effectiveness. Olivier Picard (NPA) warned of a dangerous, growing black market for counterfeit tablets. The MHRA urged reporting adverse events via the Yellow Card scheme and reiterated that the medicine is prescription-only.
Criticism & Opposition
Professor Susan Jebb (University of Oxford) cautioned GLP-1 drugs are not a quick fix and must be paired with diet and exercise. Pharmacists note missing the fasting window reduces efficacy and raises gastrointestinal side-effects. Critics argue private pricing may exclude lower-income patients.
Conflicting Reports & Gaps
Price listings vary: some retailers quote £69–£99 for the 1.5 mg dose, others £99–£119. The NHS rollout timeline is unclear; NICE’s recommendation is expected within 9–12 months but no firm decision date has been announced.
Verbatim Quotes
- “we need to make sure the medicines are cost effective for the NHS [and] the taxpayer” — Adam Burt, Novo Nordisk
- “Adam Burt, Senior Director, Private Obesity at Novo Nordisk, said: “The scale of the unmet need in the UK is clear.” — Adam Burt, Novo Nordisk
- “Patients should be wary of sites offering medicines at a cost that is too good to be true or providers who are not offering consultations before prescribing.” — Olivier Picard, NPA
What’s Next
NICE is expected to issue its assessment within 9–12 months, determining NHS reimbursement. Law-enforcement continues sting operations against counterfeit sellers, and pharmacies plan to expand the pill’s availability to more stores and online platforms through August 2026.
